On the Utility of Chemical Strategies to Improve Peptide Gut Stability

被引:47
作者
Kremsmayr, Thomas [1 ]
Aljnabi, Aws [1 ]
Blanco-Canosa, Juan B. [2 ]
Tran, Hue N. T. [3 ]
Emidio, Nayara Braga [3 ]
Muttenthaler, Markus [1 ,3 ]
机构
[1] Univ Vienna, Fac Chem, Inst Biol Chem, A-1090 Vienna, Austria
[2] Inst Adv Chem Catalonia IQAC CSIC, Dept Biol Chem, Barcelona 08034, Spain
[3] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia
基金
澳大利亚研究理事会; 欧洲研究理事会;
关键词
GUANYLATE-CYCLASE-C; CYCLIC CYSTINE LADDER; D-AMINO-ACID; ORAL DELIVERY; GASTROINTESTINAL-TRACT; RECEPTOR ANTAGONISTS; BACKBONE CYCLIZATION; ENZYMATIC STABILITY; COLONIC NOCICEPTORS; OCTAPEPTIDE ANALOG;
D O I
10.1021/acs.jmedchem.2c00094
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Inherent susceptibility of peptides to enzymaticdegradation in the gastrointestinal tract is a key bottleneck in oralpeptide drug development. Here, we present a systematic analysis of (i)the gut stability of disulfide-rich peptide scaffolds, orally administeredpeptide therapeutics, and well-known neuropeptides and (ii) medicinalchemistry strategies to improve peptide gut stability. Among a broadrange of studied peptides, cyclotides were the only scaffold class toresist gastrointestinal degradation, even when grafted with non-nativesequences. Backbone cyclization, a frequently applied strategy, failed toimprove stability in intestinalfluid, but several site-specific alterationsproved efficient. This work furthermore highlights the importance ofstandardized gut stability test conditions and suggests definedprotocols to facilitate cross-study comparison. Together, our results provide a comparative overview and framework for thechemical engineering of gut-stable peptides, which should be valuable for the development of orally administered peptidetherapeutics and molecular probes targeting receptors within the gastrointestinal tract.
引用
收藏
页码:6191 / 6206
页数:16
相关论文
共 161 条
  • [1] Converting a peptide into a drug: Strategies to improve stability and bioavailability
    Adessi, C
    Soto, C
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) : 963 - 978
  • [2] Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials
    Aguirre, T. A. S.
    Teijeiro-Osorio, D.
    Rosa, M.
    Coulter, I. S.
    Alonso, M. J.
    Brayden, D. J.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2016, 106 : 223 - 241
  • [3] Chemical Re-engineering of Chlorotoxin Improves Bioconjugation Properties for Tumor Imaging and Targeted Therapy
    Akcan, Muharrem
    Stroud, Mark R.
    Hansen, Stacey J.
    Clark, Richard J.
    Daly, Norelle L.
    Craik, David J.
    Olson, James M.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (03) : 782 - 787
  • [4] Discovery, Synthesis, and Structure Activity Relationships of Conotoxins
    Akondi, Kalyana B.
    Muttenthaler, Markus
    Dutertre, Sebastien
    Kaas, Quentin
    Craik, David J.
    Lewis, Richard J.
    Alewood, Paul F.
    [J]. CHEMICAL REVIEWS, 2014, 114 (11) : 5815 - 5847
  • [5] Calculating Resin Functionalization in Solid-Phase Peptide Synthesis Using a Standardized Method based on Fmoc Determination
    Al Musaimi, Othman
    Basso, Alessandra
    de la Torre, Beatriz G.
    Albericio, Fernando
    [J]. ACS COMBINATORIAL SCIENCE, 2019, 21 (11) : 717 - 721
  • [6] [Anonymous], 2016, CLIN PHARM BIOPHARMA
  • [7] [Anonymous], 2019, United States Pharmacopeia and National Formulary (USP 42-NF 37)
  • [8] Non-invasive delivery strategies for biologics
    Anselmo, Aaron C.
    Gokarn, Yatin
    Mitragotri, Samir
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (01) : 19 - 40
  • [9] Peptidomimetics via modifications of amino acids and peptide bonds
    Avan, Ilker
    Hall, C. Dennis
    Katritzky, Alan R.
    [J]. CHEMICAL SOCIETY REVIEWS, 2014, 43 (10) : 3575 - 3594
  • [10] CHYMOTRYPTIC AND TRYPTIC CLEAVAGE OF OXYTOCIN AND VASOPRESSIN
    BARTH, T
    PLISKA, V
    RYCHLIK, I
    [J]. COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, 1967, 32 (03) : 1058 - &